FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later

Bailey, Clifford J (2019). FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later. Diabetes, Obesity and Metabolism ,

Abstract

The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone and the ACCORD trial of intensive glycaemic control.

Publication DOI: https://doi.org/10.1111/dom.13669
Divisions: Life & Health Sciences > Biosciences
Life & Health Sciences
Additional Information: This is the peer reviewed version of the following article: Bailey, C. J. (2019), FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later. Diabetes Obes Metab. Accepted Author Manuscript, which has been published in final form at https://doi.org/10.1111/dom.13669.  This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Uncontrolled Keywords: Internal Medicine,Endocrinology, Diabetes and Metabolism,Endocrinology
Full Text Link:
Related URLs: http://doi.wile ... .1111/dom.13669 (Publisher URL)
http://www.scop ... tnerID=8YFLogxK (Scopus URL)
Published Online Date: 2019-02-14
Published Date: 2019-02-14
Authors: Bailey, Clifford J ( 0000-0002-6998-6811)

Download

[img]

Version: Accepted Version

Access Restriction: Restricted to Repository staff only until 14 February 2020.


Export / Share Citation


Statistics

Additional statistics for this record